Excess visceral fat is known to pose a significant risk to health, being strongly linked to cardiovascular diseases and type 2 diabetes. Researchers from the Pennington Biomedical Research Center in the United States, Proteimax Biotechnology in Israel, and the Institute of Biomedical Sciences at the University of São Paulo (ICB-USP) conducted a clinical trial demonstrating the potential of a synthetic molecule, Pep19, to reduce visceral fat and enhance sleep quality in obese adults.
Pep19 is an artificial version of a peptide, small protein fragments naturally found in human cells. Previous studies in animal models had shown its positive effects in combating obesity, improving markers like blood sugar levels, cholesterol, and blood pressure, without the side effects associated with traditional drugs that target the central nervous system. The molecule acts on the endocannabinoid system, which regulates vital functions such as metabolism, appetite, fat breakdown, and energy production.
The recent study involved 24 volunteers aged 46 to 59, with weights between 91 and 106 kilograms and a body mass index (BMI) ranging from 30 to 35 kg/m², indicating grade I obesity. Over 60 days, participants were split into three groups: placebo, 2 mg of Pep19, and 5 mg of Pep19, administered orally before bedtime. The trial was conducted in a triple-blind fashion to ensure that neither participants, researchers, nor analysts knew who received the medication or placebo.
Key parameters assessed included body composition, quality of life, biochemical markers, and anthropometric measurements. Results revealed that the group receiving 5 mg of Pep19 experienced an average 17% reduction in visceral fat without affecting lean mass. Additionally, all participants who received the peptide reported improved sleep quality, a factor directly linked to obesity and associated risks.
An important observation was the conversion of white fat to brown fat, as highlighted by researcher Andrea Heimann from Proteimax. This transformation enhances calorie burning for energy and heat production, typically occurring in lower temperatures. While the findings are promising, the study authors emphasize the need for further research with larger participant numbers and long-term follow-up to solidify the results.
Andrea also noted the demonstrated safety, efficacy, and ease of administration of Pep19, underscoring its potential as a practical solution for metabolic disorders. Professor Emer Ferro added that ongoing studies could lead to Pep19 becoming a revolutionary solution for enhancing metabolic health and quality of life for millions of individuals. The full article can be accessed in English in the Diabetes/Metabolism Research and Reviews journal.
In conclusion, the study’s findings offer hope for a novel approach to combatting obesity-related health risks through the use of a synthetic molecule. The potential of Pep19 to reduce visceral fat, improve sleep quality, and transform white fat to metabolically active brown fat opens up new possibilities for addressing metabolic disorders and enhancing overall well-being.
- A synthetic molecule, Pep19, shows promise in reducing visceral fat and improving sleep quality in obese adults.
- The molecule targets the endocannabinoid system, regulating metabolism, appetite, fat breakdown, and energy production.
- Clinical trial results demonstrated a 17% average reduction in visceral fat with no impact on lean mass in participants receiving 5 mg of Pep19.
- Conversion of white fat to brown fat was observed, enhancing calorie burning and energy production.
Read more on jornalggn.com.br